EFFECT OF FOOD ON THE PHARMACOKINETICS OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB IN HEALTHY SUBJECTS.

被引：0
|
作者：
Lau, Y. [1 ]
Lin, T. [1 ]
Song, D. [1 ]
Gu, J. [1 ]
Yu, R. [1 ]
Joe, A. [1 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-043
引用
收藏
页码：S71 / S72
页数：2
相关论文
共 50 条
  • [1] Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
    Subbiahy, V.
    Kuraviy, S.
    Ganguly, S.
    Welch, D. R.
    Vivian, C. J.
    Mushtaq, M. U.
    Hegde, A.
    Iyer, S.
    Behrang, A.
    Ali, S. M.
    Madison, R. W.
    Venstrom, J. M.
    Jensen, R. A.
    McGuirk, J. P.
    Amin, H. M.
    Balusu, R.
    ESMO OPEN, 2021, 6 (04)
  • [2] Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
    Anke E. M. van Erp
    Melissa H. S. Hillebrandt-Roeffen
    Laurens van Houdt
    Emmy D. G. Fleuren
    Winette T. A. van der Graaf
    Yvonne M. H. Versleijen-Jonkers
    Targeted Oncology, 2017, 12 : 815 - 826
  • [3] Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
    van Erp, Anke E. M.
    Hillebrandt-Roeffen, Melissa H. S.
    van Houdt, Laurens
    Fleuren, Emmy D. G.
    van der Graaf, Winette T. A.
    Versleijen-Jonkers, Yvonne M. H.
    TARGETED ONCOLOGY, 2017, 12 (06) : 815 - 826
  • [4] Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects
    Morcos, Peter N.
    Guerini, Elena
    Parrott, Neil
    Dall, Georgina
    Blotner, Steven
    Bogman, Katrijn
    Sturm, Carolina
    Balas, Bogdana
    Martin-Facklam, Meret
    Phipps, Alex
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (04): : 388 - 397
  • [5] EFFECT OF A PROTON PUMP INHIBITOR ON THE PHARMACOKINETICS OF THE BRUTON'S TYROSINE KINASE INHIBITOR, EVOBRUTINIB, IN HEALTHY SUBJECTS.
    Mitchell, D.
    Port, A.
    Schmidt, R.
    Scheible, H.
    Bachmann, A.
    Mammasse, N.
    Dyroff, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S66 - S66
  • [6] Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects.
    Khosravan, R
    Grabowski, B
    Wu, JT
    Joseph-Ridge, N
    Vernillet, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P50 - P50
  • [7] THE EFFECT OF FOOD AND RABEPRAZOLE ON THE PLASMA PHARMACOKINETICS OF LORLATINIB IN HEALTHY SUBJECTS.
    Xu, H.
    O'Gorman, M. T.
    Nepal, S.
    Ginman, K.
    Bergeron, M. J.
    Lee, K. C.
    Fumagalli, L.
    da Costa, L. Mendes
    Pithavala, Y. K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S93 - S93
  • [8] Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects followingoral administration
    Zhou, Sufeng
    Liu, Wei
    Zhou, Chen
    Zhang, Lingling
    Xie, Lijun
    Xu, Zhaoqiang
    Wang, Lu
    Zhao, Yuqing
    Guo, Lian
    Chen, Juan
    Ding, Lieming
    Mao, Li
    Tao, Yi
    Zhang, Chen
    Ding, Sijia
    Shao, Feng
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (06) : 719 - 730
  • [9] Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration
    Sufeng Zhou
    Wei Liu
    Chen Zhou
    Lingling Zhang
    Lijun Xie
    Zhaoqiang Xu
    Lu Wang
    Yuqing Zhao
    Lian Guo
    Juan Chen
    Lieming Ding
    Li Mao
    Yi Tao
    Chen Zhang
    Sijia Ding
    Feng Shao
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 719 - 730
  • [10] EFFECT OF RIFAMPIN ON THE PHARMACOKINETICS OF ERTUGLIFLOZIN IN HEALTHY SUBJECTS.
    Kumar, V.
    Sahasrabudhe, V.
    Liang, Y.
    Matschke, K.
    Shi, H.
    Fountaine, R. J.
    Hickman, A.
    Saur, D.
    Terra, S. G.
    Cutler, D. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S47 - S47
12345